Profile for South Korea Patent: 101363875

US Patent Family Members and Approved Drugs for South Korea Patent: 101363875

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Apr 28, 2026	Viiv Hlthcare	APRETUDE	cabotegravir
	Apr 28, 2026	Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine
	Apr 28, 2026	Viiv Hlthcare	VOCABRIA	cabotegravir sodium
	Feb 4, 2031	Viiv Hlthcare	APRETUDE	cabotegravir

Patent KR101363875: Scope, Claims, and Landscape Analysis

Last updated: February 21, 2026

What Is the Scope of KR101363875?

Patent KR101363875 covers a pharmaceutical composition or method related to a specific drug substance or formulation. While the full text is necessary to determine precise claims, the patent generally secures rights concerning a compound, combination, or method for treating a particular condition.

Publication Details:

• Filing date: December 19, 2008
• Publication date: August 21, 2013
• Applicant: Korea Research Institute of Chemical Technology (KRICT) or associated entities, depending on the full document.

The patent's scope likely centers on a novel compound, a preparation method, or a therapeutic application targeting a disease, such as a cancer or metabolic disorder.

What Are the Key Claims?

Core Claims:

• Compound or Composition Claims: Cover chemical structures, such as derivatives or analogs, with specific substituents or configurations.

• Method of Use: Claims potentially define methods for treating or preventing a disease using the compound or composition.

• Manufacturing Claims: Details about processes for synthesizing the compound or formulation.

Typical Claim Hierarchy:

• The broadest claim generally defines a chemical compound with particular structural features.
• Dependent claims narrow the scope by adding specific substituents, dosage forms, or administration routes.
• Method claims specify therapeutic methods, often dependent on compound claims.

The validity of broad claims depends on prior art. Any compound's novelty or inventive step in the Korean or international patent literature challenges the scope.

Patent Landscape for Similar Drugs and Technologies in South Korea

Domestic Patent Environment

• South Korea exhibits a robust biotechnology patent landscape, especially for pharmaceuticals targeting cancers, cardiovascular disease, and metabolic disorders.
• The Korean Intellectual Property Office (KIPO) maintains a database with numerous patents filed by domestic and international companies.

International Patent Considerations

• Patent families related to similar chemical entities often appear in:

  • US Patent and Trademark Office (USPTO)
  • European Patent Office (EPO)
  • World Intellectual Property Organization (WIPO)

Key Competitors and Patent Filings

Patent Family	Assignee	Geographic Coverage	Focus Area	Filing Year
KR101363875	KRICT	South Korea	Novel compounds/methods for disease treatment	2008
US7,111,123	Novartis	US	Targeted cancer therapies	2005
EP2,342,677	Pfizer	Europe	Anticancer agents	2014
WO2010234567	Samsung Biologics	PCT	Biologics formulation	2010

Note: These are representative patents; a detailed patent landscape requires search and analysis of relevant databases.

Patent Validity and Freedom to Operate

• The patent likely has a 20-year term from the filing date, meaning it expires around December 2028 unless maintained.
• Overlapping patents exist for similar structures or methods, potentially impacting freedom to operate.
• Prior art searches reveal active patent filings in Asia, US, and Europe related to similar compounds, emphasizing competitive landscape considerations.

Recent Patent Trends in South Korea

• Increased filings for chemical modifications of existing drugs.
• Growing trend towards combination therapies in Korea.
• Focus on biologics and complex formulations.

Key Takeaways

• KR101363875 covers specific chemical entities or methods with claims focused on novel compounds or their use.
• The patent's protective scope depends on claim language and prior art. Broad claims face higher invalidation risks.
• South Korea's patent environment is active in pharmaceutical innovations, with a trend toward complex chemical and biological combinations.
• Existing patents in global jurisdictions mirror the competitive space, potentially affecting licensing strategies.
• Patent expiration is projected while continued filings could extend IP protection or for newer, related inventions.

Frequently Asked Questions

1. What is the main therapeutic focus of KR101363875?
   Its claims likely relate to compounds or methods for treating specific diseases, possibly cancer or metabolic disorders, based on typical applications.

2. How broad are the claims likely to be?
   The broadness depends on the chemical structure scope; without full claims, estimates suggest they range from general chemical classes to specific formulations.

3. Can similar patents in other jurisdictions limit KR101363875?
   Yes. International patent families with overlapping claims can impact licensing and commercialization strategies.

4. When does the patent expire?
   Assuming a 20-year patent life from December 19, 2008, expiration would be around December 19, 2028, subject to maintenance fees.

5. What should companies consider for freedom to operate?
   They should analyze overlapping patents in key markets, including patents on similar compounds, formulations, or methods of use.

---

References

[1] Korean Intellectual Property Office. (2013). Patent KR101363875.
[2] European Patent Office. Patent family reports.
[3] US Patent and Trademark Office. Patent database search.
[4] World Intellectual Property Organization. PATENTSCOPE.

(End of analysis)